Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

Lindemann, K

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 08 2016 - 1505-10 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdw238 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab--therapeutic use
CA-125 Antigen--genetics
Disease Progression
Disease-Free Survival
Doxorubicin--therapeutic use
Drug Resistance, Neoplasm--genetics
Female
Humans
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Platinum--therapeutic use
Prognosis
Response Evaluation Criteria in Solid Tumors